

MEDICAMEN Biotech Limited



Regd. & Corp. Office:
1506, Chiranjiv Tower,
43, Nehru Place,
New Delhi - 110019 (INDIA)

Ref: STEX/OUTCOME/2025-26

Tel.: 011 - 47589500-51 (50 Lines),
E-mail: info@medicamen.com
Web: www.medicamen.com
CIN No.: L74899DL1993PLC056594
Date: 30.05.2025

BSE Limited 25th Floor Phiroze Jeebhoy Towers Dalal Street, Mumbai 400 001 BSE Code-531146	National Stock Exchange of India Limited Exchange Plaza, C-1, Block - G Bandra Kurla Complex Bandra (East) Mumbai - 400 051 NSE Code: MEDICAMEQ
--	--

Sub. : Outcome of Board Meeting

Dear Sir,

We wish to inform you that the Board of Directors of the Company at its meeting held today approved the Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and year ended on March 31, 2025.

Pursuant to Regulation 30 & 33 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose the following:

- Statement showing the Audited Financial Results (Standalone & Consolidated) of the Company for the quarter and year ended on March 31, 2025 as **Annexure-A** and
- Statutory Audit Report on the Audited Financial Results (Standalone & Consolidated) of the Company for the quarter and year ended on March 31, 2025 as **Annexure-B**

Further Board of Directors at their meeting approved the following resolutions:

- Recommended a final dividend @ 10% on Equity Shares of Rs. 10/- each i.e. Re 1/- per Equity Share for the Financial Year 2024-25 subject to the approval of shareholders at the ensuing Annual General Meeting (AGM) of the Company.
- Appointment of M/s SPB & Co., Cost Accountants as Cost Auditor of the Company for the financial year 2025-26.
- Appointment of M/s Cheena & Associates as Internal Auditor of the Company for the financial year 2025-26.
- Based on the recommendation of Audit Committee and subject to the approval of shareholders approved appointment of M/s AMJ & Associates, Practicing Company Secretaries as Secretarial Auditor of the Company for a term of 5 (five) years to conduct secretarial audit of the company from FY 2025-26 to FY 2029-30. Brief profile of M/s AMJ & Associates, Company Secretaries as **Annexure- C**

Please note that the reports of Auditors are with unmodified opinion with respect to the Audited Financial Results of the Company for the quarter/financial year ended March 31, 2025.

Please also find enclosed herewith declaration as per Regulation 33(3)(d) of SEBI (LODR), 2015 in respect of Auditor's Report with un-modified opinion for the Audited Financial Results for the quarter and year ended 31st March 2025.



Works: SP-1192, A & B Phase-IV, Industrial Area, Distt. Alwar, Bhiwadi - 301019 (Rajasthan),

Works: Unit-I : Plot No.: 86 & 87, Sector-6A, Unit-II : Plot No. : 84 & 85, Sector-6A, IIE, SIDCUL, BHEL, Ranipur, Haridwar - 249403. (Uttarakhand)

MEDICAMEN Biotech Limited



Regd. & Corp. Office:
1506, Chiranjiv Tower,
43, Nehru Place,
New Delhi - 110019 (INDIA)

Tel.: 011 - 47589500-51 (50 Lines),
E-mail: info@medicamen.com
Web: www.medicamen.com
CIN No.: L74899DL1993PLC056594

The meeting of the Board of Directors commenced on 04.30 p.m. and concluded at 06.30 p.m.

The Audited Financial Results (Standalone & Consolidated) of the Company for the quarter and year ended on March 31, 2025, as approved by the Board, will also be available on the Company's website www.medicamen.com.

This is for your information and records.

Thanking You.

Yours faithfully,
For Medicamen Biotech Limited



Parul Choudhary
Company Secretary ★
ACS44157

Works: SP-1192, A & B Phase-IV, Industrial Area, Distt. Alwar, Bhiwadi - 301019 (Rajasthan),

Works: Unit-I : Plot No.: 86 & 87, Sector-6A, **Unit-II :** Plot No. : 84 & 85, Sector-6A, IIE, SIDCUL, BHEL, Ranipur, Haridwar - 249403, (Uttarakhand)



MEDICAMEN BIOTECH LIMITED

Regd. Office: 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019
CIN : L74899DL1993PLC056594

E-mail : cs@medicamen.com, Website: www.medicamen.com

Audited Standalone and Consolidated Financial Results for the Quarter and Year ended 31st March 2025

PART I	Rupees in Lacs (Except per Share Data)											
	Standalone						Consolidated					
	Three Month period Ended			Year Ended			Three Month period Ended			Year Ended		
Particulars	31.03.2025 Audited	31.12.2024 Unaudited	31.03.2024 Audited	31.03.2025 Audited	31.03.2024 Audited	31.03.2025 Audited	31.12.2024 Unaudited	31.03.2024 Audited	31.03.2025 Audited	31.03.2024 Audited	31.03.2025 Audited	
1	Income from operations (a) Net Sales / Income from operations (b) Other Income (c) Total Revenue	2,599.54 521.95 3,121.50	4,114.23 14.08 4,128.31	4,500.73 54.31 4,555.04	15,146.33 622.51 15,768.85	17,238.62 230.26 17,468.88	2,961.29 522.73 3,484.02	4,514.22 14.07 4,528.29	4,731.95 56.62 4,788.57	16,254.72 624.39 16,879.10	17,930.62 232.57 18,163.19	
2	Expenses a) Cost of Material Consumed b) Purchase of Goods Traded c) Changes in Inventory of Finished Goods and Work in Progress d) Employees Benefits Expenses e) Finance Cost f) Depreciation and Amortisation Expenses g) Other expenses Total Expenses	1,091.04 - 213.54 552.28 62.27 46.61 852.11 2,817.86	2,787.80 - (608.98) 544.07 73.25 217.26 767.14 3,780.54	2,264.52 - 55.62 588.02 186.68 177.31 910.38 4,182.53	8,883.33 - (608.08) 2,157.02 304.54 695.30 3,058.38 14,490.50	10,469.80 - (1,331.70) 2,211.84 437.71 700.84 3,291.60 15,780.09	1,151.73 - 224.73 839.81 64.99 47.89 905.85 3,234.98	2,852.24 - (620.17) 800.49 75.95 220.97 811.12 4,140.59	2,182.33 - 177.29 839.21 188.69 177.44 958.05 4,523.01	9,064.97 - (603.17) 3,187.29 315.61 706.61 3,219.79 15,891.10	10,469.80 - (1,210.03) 3,006.58 439.72 709.32 3,440.24 16,855.63	
3	Profit/(Loss) before Exceptional Items & Tax (1 - 2)	303.63	347.77	372.51	1,278.34	1,688.79	387.70	249.03	265.56	988.00	1,307.56	
4	Exceptional Items (Commercial Tax Expenses Related to Earlier Years)	-	-	-	-	-	-	-	-	-	-	
5	Profit/(Loss) before Extra Ordinary Items & Tax (3 - 4)	303.63	347.77	372.51	1,278.34	1,688.79	387.70	249.03	265.56	988.00	1,307.56	
6	Tax Expenses Current Year MAT Credit Entitlement Deferred Tax Liability Total Tax Expense	72.57 - (9.91) 62.66	102.57 - (7.07) 95.50	79.12 - (16.92) 62.20	363.95 (31.52) 332.43	421.69 (62.70) 358.99	72.57 -9.91 62.66	102.57 (7.07) 95.50	79.12 (17.60) 61.52	363.95 (31.52) 332.43	421.69 (63.53) 358.16	
7	Net Profit / Loss for the period from Continuing operation (5- 6)	240.97	252.27	310.31	945.91	1,329.80	292.20	186.37	204.04	655.57	949.40	



Particulars	Consolidated									
	Standalone									
	Three Month period Ended		Year Ended		Year Ended		Three Month period Ended		Year Ended	
31.03.2025 Audited	31.12.2024 Unaudited	31.03.2024 Audited	31.03.2025 Audited	31.03.2024 Audited	31.03.2025 Audited	31.03.2024 Audited	31.12.2024 Unaudited	31.03.2024 Audited	31.03.2025 Audited	31.03.2024 Audited
8 Other Comprehensive Income Item that will not be reclassified to Profit & Loss	-	-	-	-	-	-	-	-	-	-
9 Total Comprehensive Income net of Tax	240.97	252.27	310.31	945.91	1,329.80	186.37	292.20	204.04	655.57	949.40
10 Net Profit /Loss attributable to a) Controlling Interest b) Non-controlling Interest										
10 Paid up equity share capital (Rs. 10/- per share)	1,271.46	1,271.46	1,271.46	1,271.46	1,271.46	241.62 (55.25)	347.45 (55.25)	212.78 (8.74)	710.82 (55.25)	1,093.10 (143.70)
11 Earning Per Share (Rs.)										
Basic	1.90	1.98	2.45	7.44	10.50	1.47	2.30	1.61	5.16	7.50
Diluted	1.90	1.98	2.45	7.44	10.50	1.47	2.30	1.61	5.16	7.50

NOTES :

- The audited financial results for the quarter and year ended on 31.03.2025 have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 30th May, 2025
- This statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- The company operates only in one business segment, viz. Pharmaceuticals formulations, hence segment reporting is not applicable
- The Earning Per Share has been calculated as per Indian Accounting Standard (Ind AS) 33 "Earning per Share"
- Audit Report has been carried out by the Statutory Auditors for the above period.
- The figures are regrouped in previous year also, wherever considered necessary, to make them comparable.

Place : New Delhi
Dated : 30.05.2025

For & on behalf of Board of Directors
Medicamen Biotech Limited



(Rahul Bishnoi)
Chairman


MEDICAMEN BIOTECH LIMITED
1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019
CIN : L74899DL 1993PLC056594

STANDALONE STATEMENT OF PROFIT & LOSS ACCOUNT FOR THE PERIOD 1ST APRIL'2024 TO 31ST MARCH'2025

PARTICULARS	Note No.	31.03.2025 (Amount Rs. Lacs)	31.03.24 (Amount Rs. Lacs)
I. Revenue from operations:			
Sale of Products	25	14,924.22	17,096.02
Other Operating Revenues		222.12	142.60
		15,146.33	17,238.63
II. Other Income	26	622.51	230.26
III. Total Revenue (I + II)		15,768.85	17,468.89
IV. Expenditure			
Cost of Materials Consumed	27	8,883.33	10,469.80
Changes in inventories of finished goods and work-in-progress	28	-608.08	-1,331.70
Employee benefits expense	29	2,157.02	2,211.84
Finance Costs	30	304.54	437.71
Depreciation and amortization expense	31	696.21	700.84
Other expense	32	3,028.88	3,263.10
Corporate Social Responsibilities (CSR) Expenses	33	29.50	28.50
Total Expense		14,491.41	15,780.09
V. Profit before exceptional items and tax (III-IV)		1,277.44	1,688.79
VI. Exceptional Items		-	-
VII. Profit/(loss) before tax (V-VI)		1,277.44	1,688.79
VIII. Tax expense:			
(1) Current tax		363.95	421.69
(2) Deferred tax		-31.25	-62.70
Total Tax Expenses		332.69	358.99
IX. Profit (Loss) for the period from continuing Operations (VII-VIII)		944.75	1,329.80
X Earnings per equity share:- Basic & Diluted		7.43	10.50
XI Weighted average number of equity Shares		1,27,14,600.00	1,26,59,277.00

For and on behalf of the Board
Medicamen Biotech Limited

R. Bishnoi
Ranul Bishnoi
Chairman
(DIN: 00317560)



Place : New Delhi
Date: 30.05.2025

MEDICAMEN BIOTECH LIMITED

1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019


CIN : L74899DL 1993PLC056594

STANDALONE BALANCE SHEET AS AT 31.03.2025

PARTICULARS	Note No.	31.03.2025 (Amount Rs. Lacs)	31.03.2024 (Amount Rs. Lacs)
I. ASSETS			
Non-current assets			
Property, plant and Equipment	3	8,531.55	9,020.61
Other Intangible Assets	4	74.23	89.83
Capital work-in-progress	5	-	-
Financial Assets			
Investments	6	806.14	775.65
Trade Receivables		-	-
Loans & Advance	7	124.46	120.19
Deferred Tax Assets (net)	8	280.47	249.22
Other non-current assets	9	4,125.30	3,928.38
Total Non Current Assets		13,942.15	14,183.87
Current assets			
Inventories	10	6,213.74	5,932.62
Financial Assets			
Investments		-	-
Trade Receivables	11	5,861.94	4,828.58
Cash and cash equivalents	12	358.03	1,462.03
Loans & Advance	13	308.85	447.80
Other Current Assets	14	2,608.48	2,566.29
Interunit		-	-
Total Current Assets		15,351.04	15,237.32
TOTAL ASSETS		29,293.19	29,421.19
II. EQUITY AND LIABILITIES			
Equity			
Share Capital	15	1,271.46	1,271.46
Other Equity	16	20,466.69	19,649.10
Total Equity		21,738.15	20,920.56
Non-current liabilities			
Financial Liabilities			
Borrowings	17	76.39	95.07
Provisions	18	220.44	175.58
Deferred Tax Liabilities (net)	19	-	-
Other non-current liabilities		-	-
Total Non Current Liabilities		296.83	270.65
Current Liabilities			
Financial Liabilities			
Borrowings	20	2,645.47	2,863.57
Trade payables	21	4,115.63	3,797.43
Other Current liabilities	22	84.92	1,070.44
Provisions	23	81.35	92.27
Current tax liabilities (Net)	24	330.84	406.27
Total Current Liabilities		7,258.21	8,229.98
TOTAL EQUITY & LIABILITIES		29,293.19	29,421.19
Significant Accounting Policies	1 & 2		

For and on behalf of the Board
Medicamen Biotech Limited

R. Bishnoi
Rahul Bishnoi
Chairman
(DIN: 00317960)




Place : New Delhi
Date: 30.05.2025

MEDICAMEN BIOTECH LIMITED
1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019
CIN : L74899DL 1993PLC056594
STANDALONE CASH FLOW STATEMENT FOR THE PERIOD 01.04.2024 TO 31.03.2025

Particulars	(All Fig. in Rs. Lacs)	
	For the year ended 31 st March, 2025	For the year ended 31 st March, 2024
<u>CASH FLOW FROM OPERATING ACTIVITIES</u>		
Net Profit/(Loss) after tax from continuing operations	944.75	1,329.80
Non-cash adjustment to reconcile profit before tax to net cash flows		
Provision for Taxation	363.95	421.69
Adjustment for Deffered Tax	31.25	-62.70
Financial Charges	304.54	437.71
Loss/(profit) on sale of fixed assets		-0.03
Depreciation/amortization on continuing operation	696.21	700.84
Interest income	-49.92	-71.42
Operating profit before working capital changes	2,290.78	2,755.89
Movement of working capital		
Increase/(decrease) in trade payables	318.20	-753.31
Increase / (decrease) in long-term provisions	44.86	9.57
Increase / (decrease) in short-term provisions	-450.29	-365.94
Increase/(decrease) in other current liabilities	-985.52	349.61
Decrease/(increase) in trade receivables	-1,033.36	1,193.96
Decrease/(increase) in inventories	-281.12	-1,426.89
Decrease / (increase) in long-term loans and advances	-4.27	-11.25
Decrease / (increase) in short-term loans and advances	138.95	242.55
Decrease/(increase) in other current assets	92.81	274.21
Decrease/(increase) in other Non-current assets	-196.92	-1,986.52
Direct taxes paid	-135.00	-306.50
Net cash flow from/ (used in) operating activities (A)	-200.88	-24.62
<u>CASH FLOWS FROM INVESTING ACTIVITIES</u>		
Purchase of fixed assets including intangible & CWIP	-191.42	-574.91
Purchase of non-current investments	-30.49	-368.00
Interest received	49.92	71.42
Net cash flow from/(used in) investing activities (B)	-171.99	-871.49
<u>CASH FLOWS FROM FINANCING ACTIVITIES :</u>		
Proceeds from issuance of share capital	-	6.35
Proceeds from Securities Premium	-	331.35
Shares Warrants	-	-
Long-term borrowings net of repayment / Repayment	-81.34	8.11
Proceeds from short-term borrowings	-218.10	532.26
Interest paid	-304.54	-437.71
Dividends paid on equity shares	-127.15	-126.51
Net cash flow from/(used in) in financing activities (C)	-731.13	313.85
Net increase/(decrease) in cash and cash equivalents (A + B + C)	-1,104.00	-582.26
Cash and cash equivalents at the beginning of the year	1,462.03	2,044.29
Cash and cash equivalents at the end of the year	358.03	1,462.03

For and on behalf of the Board
Medicamen Biotech Limited


R. Bishnoi
Chairman
(DIN: 00317960)


Place : New Delhi
Date: 30.05.2025


MEDICAMEN BIOTECH LIMITED
1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019
CIN : L74899DL 1993PLC056594

CONSOLIDATED STATEMENT OF PROFIT & LOSS ACCOUNT FOR THE PERIOD 1st April'2022 to 31 MARCH'2023

PARTICULARS	Note No.	31.03.2025 (Amount Rs. Lacs)	31.03.2024 (Amount Rs. Lacs)
I. Revenue from operations:			
Sale of Products	25	16,032.60	17,788.02
Other Operating Revenues		222.12	142.60
		16,254.72	17,930.62
II. Other Income	26	624.39	232.57
III. Total Revenue (I + II)		16,879.10	18,163.19
IV. Expenditure			
Cost of Materials Consumed	27	9,064.97	10,469.80
Changes in inventories of finished goods and work-in-progress	28	-603.17	-1,210.03
Employee benefits expense	29	3,187.29	3,006.58
Finance Costs	30	315.61	439.72
Depreciation and amortization expense	31	706.61	709.32
Other expense	32	3,190.29	3,411.74
Corporate Social Responsibilities (CSR) Expenses	33	29.50	28.50
Total Expense		15,891.10	16,855.63
V. Profit before exceptional items and tax (III-IV)		988.00	1,307.56
VI. Exceptional Items		-	-
VII. Profit/(loss) before tax (V-VI)		988.00	1,307.56
VIII. Tax expense:			
(1) Current tax		363.95	421.69
(2) Deferred tax		-31.52	-63.53
Total Tax Expenses		332.43	358.16
IX. Profit (Loss) for the period from continuing Operations (VII-VIII)		655.57	949.40
X. Net Profit/(loss) attributable to			
Controlling Interest		710.82	1,093.10
Non Controlling Interest		-55.25	-143.70
XI. Earnings per equity share:- Basic & Diluted		5.16	7.50
XII. Weighted average number of equity Shares		12714600	12659277

For and on behalf of the Board
Medicamen Biotech Limited

R. Bishnoi
Rahul Bishnoi
Chairman
(DIN: 00317960)




MEDICAMEN BIOTECH LIMITED
1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019
CIN : L74899DL 1993PLC056594
CONSOLIDATED BALANCE SHEET AS AT 31.03.2025

PARTICULARS	Note No.	31.03.2025 (Amount Rs. Lacs)	31.03.2024 (Amount Rs. Lacs)
I. ASSETS			
Non-current assets			
Property, plant and Equipment	3	8,611.62	9,095.18
Other Intangible Assets	4	74.23	89.83
Capital work-in-progress	5	-	-
Financial Assets			
Investments	6	-	-
Trade Receivables		-	-
Loans & Advance	7	124.46	121.91
Deferred Tax Assets (net)	8	280.73	251.48
Other non-current assets	9	4,142.21	3,937.33
Total Non Current Assets		13,233.25	13,495.73
Current assets			
Inventories	10	6,213.74	5,937.52
Financial Assets			
Investments		-	-
Trade Receivables	11	6,889.97	5,525.93
Cash and cash equivalents	12	375.94	1,478.56
Loans & Advance	13	308.85	449.34
Other Current Assets	14	2,666.43	2,568.02
Interunit		-	-
Total Current Assets		16,454.93	15,959.37
TOTAL ASSETS		29,688.19	29,455.10
II. EQUITY AND LIABILITIES			
Equity			
Share Capital	15	1,271.46	1,271.46
Other Equity	16	20,006.63	19,426.97
Total Equity		21,278.09	20,698.43
Non-current liabilities			
Financial Liabilities			
Borrowings	17	373.43	125.55
Provisions	18	220.44	175.58
Deferred Tax Liabilities (net)	19	-0.31	-
Other non-current liabilities		-	-
Total Non Current Liabilities		593.56	301.13
Current Liabilities			
Financial Liabilities			
Borrowings	20	2,951.87	2,956.17
Trade payables	21	4,259.64	3,894.88
Other Current liabilities	22	192.86	1,105.93
Provisions	23	81.35	92.28
Current tax liabilities (Net)	24	330.82	406.28
Total Current Liabilities		7,816.54	8,455.54
TOTAL EQUITY & LIABILITIES		29,688.19	29,455.10
Significant Accounting Policies	1 & 2		

For and on behalf of the Board
Medicamen Biotech Limited

R. B. Bhatnagar

Rahul Bhatnagar
Chairman
(DIN: 00317960)




MEDICAMEN BIOTECH LIMITED
1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019
CIN : L74899DL 1993PLC056594
CONSOLIDATED CASH FLOW STATEMENT FOR THE PERIOD 01.04.2024 TO 31.03.2025

Particulars	(All Fig. in Rs. Lacs)	
	For the year ended 31 st March, 2025	For the year ended 31 st March, 2024
<u>CASH FLOW FROM OPERATING ACTIVITIES</u>		
Net Profit/(Loss) after tax from continuing operations	655.35	949.40
Non-cash adjustment to reconcile profit before tax to net cash flows	-	
Provision for Taxation	363.95	421.69
Adjustment for Deferred Tax	30.35	-63.53
Financial Charges	315.60	439.72
Loss/(profit) on sale of fixed assets	-	0.03
Depreciation/amortization on continuing operation	707.52	709.32
Interest income	-49.12	-72.43
Operating profit before working capital changes	2,023.65	2,384.21
Movement of working capital		
Increase/(decrease) in trade payables	379.51	-863.71
Increase / (decrease) in long-term provisions	44.86	9.57
Increase / (decrease) in short-term provisions	-450.29	-362.12
Increase/(decrease) in other current liabilities	-909.94	377.47
Decrease/(increase) in trade receivables	-1,366.89	999.88
Decrease/(increase) in inventories	-276.12	-1,431.79
Decrease / (increase) in long-term loans and advances	-4.27	-11.25
Decrease / (increase) in short-term loans and advances	138.95	243.25
Decrease/(increase) in other current assets	41.03	272.74
Decrease/(increase) in other Non-current assets	-204.87	-1,986.13
Direct taxes paid	-135.00	-306.50
Net cash flow from/ (used in) operating activities (A)	-719.38	-674.38
<u>CASH FLOWS FROM INVESTING ACTIVITIES</u>		
Purchase of fixed assets including intangible & CWIP	-207.33	-628.72
Purchase of non-current investments	-30.49	-
Interest received	49.12	72.43
Net cash flow from/(used in) investing activities (B)	-188.70	-556.29
<u>CASH FLOWS FROM FINANCING ACTIVITIES :</u>		
Proceeds from issuance of share capital	86.50	6.35
Proceeds from Securities Premium	-	183.31
Shares Warrants	-	-
Capital Reserve	-	344.47
Long-term borrowings net of repayment / Repayment	166.54	38.59
Proceeds from short-term borrowings	-4.30	624.86
Interest paid	-315.60	-439.72
Dividends paid on equity shares	-127.15	-126.51
Income Tax Provision Reverse for earlier year	-	-
Preferential issue Expenditure	-	-
Net cash flow from/(used in) in financing activities (C)	-194.01	631.35
Net increase/(decrease) in cash and cash equivalents (A + B + C)	-1,102.09	-599.32
Cash and cash equivalents at the beginning of the year	1,477.10	2,077.88
Cash and cash equivalents at the end of the year	375.01	1,478.56

For and on behalf of the Board
Medicamen Biotech Limited

R. B. Bishnoi
Rahul Bishnoi
Chairman
(DIN: 00317960)



**INDEPENDENT AUDITOR'S REPORT ON AUDIT OF ANNUAL STANDALONE
FINANCIAL RESULTS AND REVIEW OF QUARTERLY FINANCIAL RESULTS**

TO THE BOARD OF DIRECTORS OF MEDICAMEN BIOTECH LIMITED

Report on the audit of the Standalone Financial Results

Opinion

We have audited the accompanying statement of quarterly and year to date financial results of Medicamen Biotech Limited (the "Company") for the quarter ended March 31, 2025 and for the year ended March 31, 2025 ("Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulation").

a. Opinion on Annual Standalone Financial Results

In our opinion and to the best of our information and according to the explanations given to us, the Statement:

- i. is presented in accordance with the requirements of the Listing Regulations in this regard; and
- ii. gives a true and fair view in conformity with the applicable accounting standards and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information of the Company for the quarter ended March 31, 2025 and for the year ended March 31, 2025.

b. Conclusion on Unaudited Standalone Financial Results for the Quarter ended on March 31, 2025

With respect to the Standalone Financial Results for the quarter ended on March 31, 2025 based on our review conducted as stated in paragraph (b) of Auditor's Responsibilities section below, nothing has come to our attention that causes us to believe that the Standalone Financial Results for the quarter ended March 31, 2025, prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements), Regulations, 2015 as amended, including the manner in which it is to be disclosed, or that contains any material misstatement.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013, as amended ("the Act"). Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the Financial Results" section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in

accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.

Management's Responsibilities for the Financial Results

The Statement has been prepared on the basis of the annual financial statements. The Board of Directors of the Company are responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit and other comprehensive income of the Company and other financial information in accordance with the applicable accounting standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Statement, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Results

Audit of the Standalone Financial Results for the year ended March 31, 2025

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(1) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatement in the Annual Standalone Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Annual Standalone Financial Results may be influenced. We consider qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Annual Standalone Financial Results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

The Statement includes the results for the quarter ended March 31, 2025 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2025 and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subjected to a limited review by us, as required under the Listing Regulations.

For Rai Qimat & Associates
Chartered Accountants



(Membership Number: 013152C)
UDIN:25080857BMLCPJ8565

Place: Gurugram
Date: 30.05.2025

**INDEPENDENT AUDITOR'S REPORT ON AUDIT OF ANNUAL CONSOLIDATED
FINANCIAL RESULTS AND REVIEW OF QUARTERLY FINANCIAL RESULTS**

TO THE BOARD OF DIRECTORS OF MEDICAMEN BIOTECH LIMITED

Report on the audit of the Consolidated Financial Results

Opinion

We have audited the accompanying statement of quarterly consolidated financial results of Medicamen Biotech Limited ("Holding Company"), which includes its subsidiaries (the Holding company and its subsidiaries together referred to as 'the Group') for the quarter and year ended March 31, 2025 ("Statement"), attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

a. Opinion on Annual Consolidated Financial Results

In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of the reports of the other auditors on separate audited financial statements of the subsidiaries/controlled entity, the Statement includes the results of the following entities:

- i. Subsidiaries
Opal Pharmaceuticals (Pty) Ltd
Medicamen Life Sciences Private Limited
- ii. is presented in accordance with the requirements of the Listing Regulations in this regard; and
- iii. gives a true and fair view in conformity with the applicable accounting standards, and other accounting principles generally accepted in India, of the consolidated net profit and other comprehensive loss and other financial information of the Group for the quarter and year ended March 31, 2025.

b. Conclusion on Unaudited Consolidated Financial Results for the Quarter ended on March 31, 2025

With respect to the Consolidated Financial Results for the quarter ended on March 31, 2025 based on our review conducted as stated in paragraph (b) of Auditor's Responsibilities section below, nothing has come to our attention that causes us to believe that the Standalone Financial Results for the quarter ended March 31, 2025, prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements), Regulations, 2015 as amended, including the manner in which it is to be disclosed, or that contains any material misstatement.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs), as specified under Section 143(10) of the Companies Act, 2013, as amended ("the Act"). Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the Consolidated Financial Results" section of our report. We are independent of the Group and its subsidiaries in accordance with the 'Code of Ethics' issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the consolidated financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us and other auditors in terms of their reports referred to in "Other Matter" paragraph below, is sufficient and appropriate to provide a basis for our opinion.

Management's Responsibilities for the Consolidated Financial Results

The Statement has been prepared on the basis of the consolidated annual financial statements. The Holding Company's Board of Directors are responsible for the preparation and presentation of the Statement that give a true and fair view of the net profit and other comprehensive loss and other financial information of the Group in accordance with the applicable accounting standards prescribed under section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Statement by the Directors of the Holding Company, as aforesaid.

In preparing the Statement, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the management either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are also responsible for overseeing the financial reporting process of the Group.

Auditor's Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement. As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances- Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial statements and other results/financial information of the entities within the Group to express an opinion on the Statement. We are responsible for the direction, supervision and performance of the audit of the financial information of such entities included in the Statement of which we are the independent auditors. For the other entities included in the Statement, which have been audited by other auditors, such other auditors remain responsible for the direction supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

Materiality is the magnitude of misstatement in the Annual Standalone Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Annual Standalone Financial Results may be influenced. We consider qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Annual Standalone Financial Results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards

We also performed procedures in accordance with the Circular No. CIR/CFD/CMDI/4412019 dated March 29, 2019 issued by the Securities Exchange Board of India under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

Other Matter

The accompanying Statement includes the audited financial results, in respect of two subsidiaries, whose financial results/statements include total assets of Rs. 1199.97 lakhs as at March 31, 2025, total revenues of for the quarter ended is Rs. 362.52 lakhs and for the year ended is 1110.25 Lakhs , total net profit (loss) after tax of for the quarter ended is Rs. (54.6) and for the year ended is (290.34) lakhs for the year ended on March 31, 2025 as considered in the Statement which have been audited by their respective independent auditors.

The independent auditor's report on the standalone financial results of these entities have been furnished to us by the Management and our opinion on the Statement in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the reports of such auditors and the procedures performed by us as stated in paragraph 10 above.

**For Rai Qimat & Associates
Chartered Accountants**


GURUGRAM
Qimat Raj Garg
Partner

(Membership Number: 013152C)
UDIN:25080857BMLCPL8205

Place: Gurugram

Date: 30.05.2025

Annexure – C

Disclosure of information from the Secretarial Auditor upon Appointment

Sr. No.	Particulars	Details
1.	Reason for change viz. appointment, resignation, removal, death or otherwise;	The Board has recommended the appointment of M/s. AMJ & Associates. Practicing Company Secretaries as Secretarial Auditors of the Company, for the approval of the Members at the ensuing 32 nd Annual General Meeting.
2.	Date of appointment /cessation (as applicable) & term of	For a term five consecutive years i.e. from the conclusion of this 32 nd Annual General Meeting till 37 th Annual General Meeting
3.	Brief Profile	M/s AMJ & Associates, Company Secretaries is a reputed firm of Practicing Company Secretaries committed to delivering strategic, research-driven, and customized corporate advisory solutions. With a team of seasoned professionals, the firm brings deep domain expertise in Corporate Laws, Insolvency & Bankruptcy, Securities Laws, FEMA and Corporate Restructuring. The firm also offers comprehensive support in Compliance Management, Regulatory Approvals, and Legal Documentation, serving clients across a diverse range of industries.
4.	Disclosure of relationships between directors	Not Applicable

Tarun



MEDICAMEN Biotech Limited



Regd. & Corp. Office:
1506, Chiranjiv Tower,
43, Nehru Place,
New Delhi - 110019 (INDIA)
Date: 30.05.2025

Tel.: 011 - 47589500-51 (50 Lines),
E-mail: info@medicamen.com
Web: www.medicamen.com
CIN No.: L74899DL1993PLC056594

To

BSE Limited 25th Floor Phiroze Jeejebhoy Towers Dalal Street, Mumbai 400 001 BSE Code-531146	National Stock Exchange of India Limited Exchange Plaza, C-1, Block - G Bandra Kurla Complex Bandra (East) Mumbai – 400 051 NSE Code: MEDICAMEQ
--	--

Subject: Declaration pursuant to Regulation 33 (3) (d) of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”)

Pursuant to Regulation 33 (3) (d) of the Listing Regulations, as amended by the SEBI (Listing Obligations and Disclosure Requirements) (Amendment) Regulations, 2016, vide notification no. SEBI/LAD-NRO/GN/2016-17/001 dated May 25, 2016, Circular No CIR/CFD/CMD/56/2016 dated May 27, 2016 and Circular No CIR/CFD/CMD/56/2016 dated July 5, 2016, we hereby declare that M/s Rai Qimat & Associates, Chartered Accountants (Firm Registration No 013152C), statutory auditors of the Company have issued audit report with unmodified opinion on the audited financial results of the Company (Standalone & Consolidated) for the financial year ended on March 31, 2025.

This is for your information and record.

Thanking you

Yours truly
For Medicamen Biotech Limited


Rahul Bishnoi
Director
DIN: 00317960

